Finch Therapeutics Group Stock Current Liabilities
FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Finch Therapeutics Group fundamentals help investors to digest information that contributes to Finch Therapeutics' financial success or failures. It also enables traders to predict the movement of Finch Pink Sheet. The fundamental analysis module provides a way to measure Finch Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Finch Therapeutics pink sheet.
Finch |
Finch Therapeutics Group Company Current Liabilities Analysis
Finch Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Finch Therapeutics Group has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Finch Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Finch Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Finch Therapeutics could also be used in its relative valuation, which is a method of valuing Finch Therapeutics by comparing valuation metrics of similar companies.Finch Therapeutics is currently under evaluation in current liabilities category among its peers.
Finch Fundamentals
Return On Equity | -0.63 | ||||
Return On Asset | -0.22 | ||||
Current Valuation | 10.74 M | ||||
Shares Outstanding | 1.61 M | ||||
Shares Owned By Insiders | 53.48 % | ||||
Shares Owned By Institutions | 11.35 % | ||||
Number Of Shares Shorted | 19.2 K | ||||
Price To Book | 0.14 X | ||||
Price To Sales | 30.46 X | ||||
Revenue | 107 K | ||||
Gross Profit | (57.03 M) | ||||
EBITDA | (32.48 M) | ||||
Net Income | (74.75 M) | ||||
Cash And Equivalents | 104.67 M | ||||
Cash Per Share | 2.19 X | ||||
Total Debt | 30.13 M | ||||
Debt To Equity | 0.35 % | ||||
Current Ratio | 7.28 X | ||||
Book Value Per Share | 11.86 X | ||||
Cash Flow From Operations | (31.5 M) | ||||
Short Ratio | 0.19 X | ||||
Earnings Per Share | (6.59) X | ||||
Price To Earnings To Growth | (0.02) X | ||||
Target Price | 90.0 | ||||
Beta | 0.46 | ||||
Market Capitalization | 1.94 M | ||||
Total Asset | 71 M | ||||
Retained Earnings | (350.39 M) | ||||
Working Capital | 21.76 M | ||||
Net Asset | 71 M |
About Finch Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Finch Therapeutics Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Finch Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Finch Therapeutics Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
CEOs Directory Screen CEOs from public companies around the world | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |